{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:01:33Z","timestamp":1790665293284,"version":"4.1.0"},"reference-count":314,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Investissements d\u2019Avenir","award":["ANR-10-IAIHU-06"],"award-info":[{"award-number":["ANR-10-IAIHU-06"]}]},{"name":"Innovative Medicines Initiative Joint Undertaking","award":["n\u00b0115568"],"award-info":[{"award-number":["n\u00b0115568"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00441-018-2813-2","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T02:56:57Z","timestamp":1520391417000},"page":"111-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Molecular basis of dopamine replacement therapy and its side effects in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"373","author":[{"given":"Hana","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Laure","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Mangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Le Febvre de Nailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Charbonnier-Beaupel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"2813_CR1","first-page":"S46","volume":"57","author":"Y Agid","year":"2001","unstructured":"Agid Y (2001) Levodopa. Is toxicity a myth? 1998. Neurology 57:S46\u2013S51","journal-title":"Neurology"},{"key":"2813_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1212\/01.WNL.0000044047.58984.2F","volume":"60","author":"JE Ahlskog","year":"2003","unstructured":"Ahlskog JE (2003) Slowing Parkinson\u2019s disease progression: recent dopamine agonist trials. Neurology 60:381\u2013389","journal-title":"Neurology"},{"key":"2813_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1111\/j.1471-4159.2007.05104.x","volume":"104","author":"MR Ahmed","year":"2008","unstructured":"Ahmed MR, Bychkov E, Gurevich VV et al (2008) Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J Neurochem 104:1622\u20131636","journal-title":"J Neurochem"},{"key":"2813_CR4","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1523\/JNEUROSCI.0837-12.2012","volume":"32","author":"C Alcacer","year":"2012","unstructured":"Alcacer C, Santini E, Valjent E et al (2012) G\u03b1(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 32:5900\u20135910","journal-title":"J Neurosci"},{"key":"2813_CR5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR), 4th edn. American Psychiatric Association, Arlington","edition":"4"},{"key":"2813_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.parkreldis.2011.03.014","volume":"17","author":"E Anderson","year":"2011","unstructured":"Anderson E, Nutt J (2011) The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord 17:587\u2013592","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","volume":"6","author":"M Andersson","year":"1999","unstructured":"Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 6:461\u2013474","journal-title":"Neurobiol Dis"},{"key":"2813_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","volume":"88","author":"A Antonini","year":"2017","unstructured":"Antonini A, Barone P, Bonuccelli U et al (2017) ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 88:317\u2013324","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.20296","volume":"57","author":"I Aubert","year":"2005","unstructured":"Aubert I, Guigoni C, H\u00e5kansson K et al (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57:17\u201326","journal-title":"Ann Neurol"},{"key":"2813_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1113\/jphysiol.1910.sp001392","volume":"41","author":"G Barger","year":"1910","unstructured":"Barger G, Dale HH (1910) Chemical structure and sympathomimetic action of amines. J Physiol 41:19\u201359","journal-title":"J Physiol"},{"key":"2813_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573\u2013580","journal-title":"Lancet Neurol"},{"key":"2813_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1046\/j.1471-4159.1995.64020825.x","volume":"64","author":"AN Basma","year":"1995","unstructured":"Basma AN, Morris EJ, Nicklas WJ, Geller HM (1995) L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64:825\u2013832","journal-title":"J Neurochem"},{"key":"2813_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2013.09.020","volume":"62","author":"MF Bastide","year":"2014","unstructured":"Bastide MF, Dovero S, Charron G et al (2014) Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. Neurobiol Dis 62:179\u2013192","journal-title":"Neurobiol Dis"},{"key":"2813_CR14","doi-asserted-by":"publisher","first-page":"14845","DOI":"10.1073\/pnas.1009874107","volume":"107","author":"HS Bateup","year":"2010","unstructured":"Bateup HS, Santini E, Shen W et al (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 107:14845\u201314850","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2813_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"J-M Beaulieu","year":"2011","unstructured":"Beaulieu J-M, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182\u2013217","journal-title":"Pharmacol Rev"},{"key":"2813_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/mds.23616","volume":"26","author":"D Berg","year":"2011","unstructured":"Berg D, Godau J, Trenkwalder C et al (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord Off J Mov Disord Soc 26:1243\u20131250","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR17","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1523\/JNEUROSCI.18-14-05301.1998","volume":"18","author":"JD Berke","year":"1998","unstructured":"Berke JD, Paletzki RF, Aronson GJ et al (1998) A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18:5301\u20135310","journal-title":"J Neurosci"},{"key":"2813_CR18","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1523\/JNEUROSCI.5884-08.2009","volume":"29","author":"A Berthet","year":"2009","unstructured":"Berthet A, Porras G, Doudnikoff E et al (2009) Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 29:4829\u20134835","journal-title":"J Neurosci"},{"key":"2813_CR19","first-page":"787","volume":"73","author":"W Birkmayer","year":"1961","unstructured":"Birkmayer W, Hornykiewicz O (1961) The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787\u2013788","journal-title":"Wien Klin Wochenschr"},{"key":"2813_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/mds.27181","volume":"32","author":"R Biundo","year":"2017","unstructured":"Biundo R, Weis L, Abbruzzese G et al (2017) Impulse control disorders in advanced Parkinson\u2019s disease with dyskinesia: the ALTHEA study. Mov Disord Off J Mov Disord Soc 32:1557\u20131565","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.parkreldis.2004.02.011","volume":"10","author":"PJ Blanchet","year":"2004","unstructured":"Blanchet PJ, Calon F, Morissette M et al (2004) Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 10:297\u2013304","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0306-4522(91)90133-9","volume":"40","author":"S Blunt","year":"1991","unstructured":"Blunt S, Jenner P, Marsden CD (1991a) The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience 40:453\u2013464","journal-title":"Neuroscience"},{"key":"2813_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0306-4522(91)90420-S","volume":"43","author":"SB Blunt","year":"1991","unstructured":"Blunt SB, Jenner P, Marsden CD (1991b) The effect of L-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography. Neuroscience 43:95\u2013110","journal-title":"Neuroscience"},{"key":"2813_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","volume":"17","author":"V Bonifati","year":"1994","unstructured":"Bonifati V, Fabrizio E, Cipriani R et al (1994) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17:73\u201382","journal-title":"Clin Neuropharmacol"},{"key":"2813_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P et al (2014a) Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord Off J Mov Disord Soc 29:229\u2013237","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P et al (2014b) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 29:1273\u20131280","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/clpt.1990.166","volume":"48","author":"B Boud\u00edkov\u00e1","year":"1990","unstructured":"Boud\u00edkov\u00e1 B, Szumlanski C, Maidak B, Weinshilboum R (1990) Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48:381\u2013389","journal-title":"Clin Pharmacol Ther"},{"key":"2813_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U et al (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211","journal-title":"Neurobiol Aging"},{"key":"2813_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ana.410360108","volume":"36","author":"D Bravi","year":"1994","unstructured":"Bravi D, Mouradian MM, Roberts JW et al (1994) Wearing-off fluctuations in Parkinson\u2019s disease: contribution of postsynaptic mechanisms. Ann Neurol 36:27\u201331","journal-title":"Ann Neurol"},{"key":"2813_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bcp.2007.06.043","volume":"75","author":"JA Brewer","year":"2008","unstructured":"Brewer JA, Potenza MN (2008) The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75:63","journal-title":"Biochem Pharmacol"},{"key":"2813_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mds.24998","volume":"27","author":"LS Brod","year":"2012","unstructured":"Brod LS, Aldred JL, Nutt JG (2012) Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 27:750\u2013753","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","volume":"30","author":"P Calabresi","year":"2007","unstructured":"Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30:211\u2013219","journal-title":"Trends Neurosci"},{"key":"2813_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S0140-6736(74)92219-3","volume":"2","author":"DB Calne","year":"1974","unstructured":"Calne DB, Teychenne PF, Leigh PN et al (1974) Treatment of parkinsonism with bromocriptine. Lancet Lond Engl 2:1355\u20131356","journal-title":"Lancet Lond Engl"},{"key":"2813_CR34","first-page":"S70","volume":"47","author":"F Calon","year":"2000","unstructured":"Calon F, Grondin R, Morissette M et al (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47:S70\u2013S78","journal-title":"Ann Neurol"},{"key":"2813_CR35","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200","journal-title":"Nature"},{"key":"2813_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1126\/science.127.3296.471","volume":"127","author":"A Carlsson","year":"1958","unstructured":"Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127:471","journal-title":"Science"},{"key":"2813_CR37","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain J Neurol 130:1819\u20131833","journal-title":"Brain J Neurol"},{"key":"2813_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00002826-198906000-00001","volume":"12","author":"JM Cedarbaum","year":"1989","unstructured":"Cedarbaum JM (1989) The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 12:147\u2013166","journal-title":"Clin Neuropharmacol"},{"key":"2813_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","volume":"30","author":"MA Cenci","year":"2007","unstructured":"Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236\u2013243","journal-title":"Trends Neurosci"},{"key":"2813_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2014.00242","volume":"5","author":"MA Cenci","year":"2014","unstructured":"Cenci MA (2014) Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 5:242","journal-title":"Front Neurol"},{"key":"2813_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1006\/exnr.2000.7433","volume":"164","author":"MA Cenci","year":"2000","unstructured":"Cenci MA, Kal\u00e9n P (2000) Serotonin release from mesencephalic raphe neurons grafted to the 5,7-dihydroxytryptamine-lesioned rat hippocampus: effects of behavioral activation and stress. Exp Neurol 164:351\u2013361","journal-title":"Exp Neurol"},{"key":"2813_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","volume":"183","author":"MA Cenci","year":"2010","unstructured":"Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209\u2013233","journal-title":"Prog Brain Res"},{"key":"2813_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","volume":"99","author":"MA Cenci","year":"2006","unstructured":"Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99:381\u2013392","journal-title":"J Neurochem"},{"key":"2813_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0306-4522(99)00294-8","volume":"94","author":"MA Cenci","year":"1999","unstructured":"Cenci MA, Tranberg A, Andersson M, Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94:515\u2013527","journal-title":"Neuroscience"},{"key":"2813_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000017294","volume":"20","author":"C Cepeda","year":"1998","unstructured":"Cepeda C, Levine MS (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20:1\u201318","journal-title":"Dev Neurosci"},{"key":"2813_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1179\/147683010X12611460763760","volume":"13","author":"E Cereda","year":"2010","unstructured":"Cereda E, Barichella M, Pezzoli G (2010) Controlled-protein dietary regimens for Parkinson\u2019s disease. Nutr Neurosci 13:29\u201332","journal-title":"Nutr Neurosci"},{"key":"2813_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.biopsych.2014.04.002","volume":"77","author":"M Cerovic","year":"2015","unstructured":"Cerovic M, Bagetta V, Pendolino V et al (2015) Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia. Biol Psychiatry 77:106\u2013115","journal-title":"Biol Psychiatry"},{"key":"2813_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neuron.2010.03.012","volume":"66","author":"JR Chalifoux","year":"2010","unstructured":"Chalifoux JR, Carter AG (2010) GABAB receptors modulate NMDA receptor calcium signals in dendritic spines. Neuron 66:101\u2013113","journal-title":"Neuron"},{"key":"2813_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1523\/JNEUROSCI.5231-13.2015","volume":"35","author":"F Charbonnier-Beaupel","year":"2015","unstructured":"Charbonnier-Beaupel F, Malerbi M, Alcacer C et al (2015) Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia. J Neurosci 35:96\u2013111","journal-title":"J Neurosci"},{"key":"2813_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464\u2013474","journal-title":"Lancet Neurol"},{"key":"2813_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.parkreldis.2016.05.017","volume":"29","author":"R Cilia","year":"2016","unstructured":"Cilia R, Benfante R, Asselta R et al (2016) Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson\u2019s disease. Parkinsonism Relat Disord 29:96\u2013103","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR52","first-page":"89","volume":"19","author":"G Cohen","year":"1983","unstructured":"Cohen G (1983) The pathobiology of Parkinson\u2019s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19:89\u2013103","journal-title":"J Neural Transm Suppl"},{"key":"2813_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1034\/j.1399-0004.2001.600204.x","volume":"60","author":"DE Comings","year":"2001","unstructured":"Comings DE, Gade-Andavolu R, Gonzalez N et al (2001) The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 60:107\u2013116","journal-title":"Clin Genet"},{"key":"2813_CR54","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin M, Martinelli P (2010) Pharmacokinetics of levodopa. J Neurol 257:S253\u2013S261","journal-title":"J Neurol"},{"key":"2813_CR55","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/BF00626370","volume":"41","author":"M Contin","year":"1991","unstructured":"Contin M, Riva R, Martinelli P et al (1991) Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson\u2019s disease. Eur J Clin Pharmacol 41:463\u2013466","journal-title":"Eur J Clin Pharmacol"},{"key":"2813_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1212\/WNL.43.2.367","volume":"43","author":"M Contin","year":"1993","unstructured":"Contin M, Riva R, Martinelli P et al (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson\u2019s disease. Neurology 43:367\u2013371","journal-title":"Neurology"},{"key":"2813_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/mds.20410","volume":"20","author":"M Contin","year":"2005","unstructured":"Contin M, Martinelli P, Mochi M et al (2005) Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 20:734\u2013739","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/mdc3.12444","volume":"4","author":"J-C Corvol","year":"2017","unstructured":"Corvol J-C, Poewe W (2017) Pharmacogenetics of Parkinson\u2019s disease in clinical practice. Mov Disord Clin Pract 4:173\u2013180 4","journal-title":"Mov Disord Clin Pract"},{"key":"2813_CR59","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1523\/JNEUROSCI.0676-04.2004","volume":"24","author":"J-C Corvol","year":"2004","unstructured":"Corvol J-C, Muriel M-P, Valjent E et al (2004) Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24:7007\u20137014","journal-title":"J Neurosci"},{"key":"2813_CR60","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","volume":"64","author":"J-C Corvol","year":"2007","unstructured":"Corvol J-C, Anzouan-Kacou J-B, Fauveau E et al (2007) Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol 64:1721\u20131726","journal-title":"Arch Neurol"},{"key":"2813_CR61","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.22155","volume":"69","author":"J-C Corvol","year":"2011","unstructured":"Corvol J-C, Bonnet C, Charbonnier-Beaupel F et al (2011) The COMT Val158Met polymorphism affects the response to entacapone in Parkinson\u2019s disease: a randomized crossover clinical trial. Ann Neurol 69:111\u2013118","journal-title":"Ann Neurol"},{"key":"2813_CR62","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJM196702162760703","volume":"276","author":"GC Cotzias","year":"1967","unstructured":"Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374\u2013379","journal-title":"N Engl J Med"},{"key":"2813_CR63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism\u2014chronic treatment with L-dopa. N Engl J Med 280:337\u2013345","journal-title":"N Engl J Med"},{"key":"2813_CR64","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.biopsych.2009.04.025","volume":"66","author":"S Darmopil","year":"2009","unstructured":"Darmopil S, Mart\u00edn AB, De Diego IR et al (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66:603\u2013613","journal-title":"Biol Psychiatry"},{"key":"2813_CR65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nn1632","volume":"9","author":"M Day","year":"2006","unstructured":"Day M, Wang Z, Ding J et al (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9:251\u2013259","journal-title":"Nat Neurosci"},{"key":"2813_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2017.02.001","volume":"151","author":"P Deurwaerd\u00e8re De","year":"2017","unstructured":"De Deurwaerd\u00e8re P, Ramsay RR, Di Giovanni G (2017) Neurobiology and neuropharmacology of monoaminergic systems. Prog Neurobiol 151:1\u20133","journal-title":"Prog Neurobiol"},{"key":"2813_CR67","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1093\/emboj\/17.15.4426","volume":"17","author":"M Deak","year":"1998","unstructured":"Deak M, Clifton AD, Lucocq LM, Alessi DR (1998) Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2\/p38, and may mediate activation of CREB. EMBO J 17:4426\u20134441","journal-title":"EMBO J"},{"key":"2813_CR68","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.parkreldis.2013.10.017","volume":"20","author":"D Devos","year":"2014","unstructured":"Devos D, Lejeune S, Cormier-Dequaire F et al (2014) Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson\u2019s disease. Parkinsonism Relat Disord 20:170\u2013175","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR69","first-page":"399","volume":"53","author":"SG Diamond","year":"1990","unstructured":"Diamond SG, Markham CH (1990) Longitudinal study of effects of early levodopa treatment on disability and mortality in Parkinson\u2019s disease. Adv Neurol 53:399\u2013403","journal-title":"Adv Neurol"},{"key":"2813_CR70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neulet.2007.04.034","volume":"419","author":"B Dumartin","year":"2007","unstructured":"Dumartin B, Doudnikoff E, Gonon F, Bloch B (2007) Differences in ultrastructural localization of dopaminergic D1 receptors between dorsal striatum and nucleus accumbens in the rat. Neurosci Lett 419:273\u2013277","journal-title":"Neurosci Lett"},{"key":"2813_CR71","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0026-895X(24)23206-5","volume":"57","author":"AW Dunah","year":"2000","unstructured":"Dunah AW, Wang Y, Yasuda RP et al (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson\u2019s disease. Mol Pharmacol 57:342\u2013352","journal-title":"Mol Pharmacol"},{"key":"2813_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/o04-121","volume":"83","author":"KL Dunn","year":"2005","unstructured":"Dunn KL, Espino PS, Drobic B et al (2005) The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol Biochim Biol Cell 83:1\u201314","journal-title":"Biochem Cell Biol Biochim Biol Cell"},{"key":"2813_CR73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1600-0404.1996.tb00163.x","volume":"93","author":"E Dupont","year":"1996","unstructured":"Dupont E, Andersen A, Boas J et al (1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93:14\u201320","journal-title":"Acta Neurol Scand"},{"key":"2813_CR74","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M et al (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381\u2013388","journal-title":"Neurology"},{"key":"2813_CR75","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/BF01485901","volume":"38","author":"H Ehringer","year":"1960","unstructured":"Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38:1236\u20131239","journal-title":"Klin Wochenschr"},{"key":"2813_CR76","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1046\/j.1360-0443.1998.93913758.x","volume":"93","author":"SA Eisen","year":"1998","unstructured":"Eisen SA, Lin N, Lyons MJ et al (1998) Familial influences on gambling behavior: an analysis of 3359 twin pairs. Addict Abingdon Engl 93:1375\u20131384","journal-title":"Addict Abingdon Engl"},{"key":"2813_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1006\/exnr.1996.6379","volume":"144","author":"JD Elsworth","year":"1997","unstructured":"Elsworth JD, Roth RH (1997) Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson\u2019s disease. Exp Neurol 144:4\u20139","journal-title":"Exp Neurol"},{"key":"2813_CR78","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ana.23881","volume":"74","author":"M Engeln","year":"2013","unstructured":"Engeln M, Fasano S, Ahmed SH et al (2013) Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann Neurol 74:140\u2013144","journal-title":"Ann Neurol"},{"key":"2813_CR79","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.21475","volume":"22","author":"G Fabbrini","year":"2007","unstructured":"Fabbrini G, Brotchie JM, Grandas F et al (2007) Levodopa-induced dyskinesias. Mov Disord Off J Mov Disord Soc 22:1379\u20131389 quiz 1523","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR80","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1212\/WNL.47.6_Suppl_3.184S","volume":"47","author":"S Fahn","year":"1996","unstructured":"Fahn S (1996) Is levodopa toxic? Neurology 47:S184\u2013S195","journal-title":"Neurology"},{"key":"2813_CR81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mds.26102","volume":"30","author":"S Fahn","year":"2015","unstructured":"Fahn S (2015) The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord Off J Mov Disord Soc 30:4\u201318","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR82","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"2813_CR83","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/jnnp-2014-307904","volume":"86","author":"ML Fantini","year":"2015","unstructured":"Fantini ML, Macedo L, Zibetti M et al (2015) Increased risk of impulse control symptoms in Parkinson\u2019s disease with REM sleep behaviour disorder. J Neurol Neurosurg Psychiatry 86:174\u2013179","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR84","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1073\/pnas.1012071107","volume":"107","author":"S Fasano","year":"2010","unstructured":"Fasano S, Bezard E, D\u2019Antoni A et al (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 107:21824\u201321829","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2813_CR85","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","volume":"14","author":"A Fasano","year":"2015","unstructured":"Fasano A, Visanji NP, Liu LWC et al (2015) Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol 14:625\u2013639","journal-title":"Lancet Neurol"},{"key":"2813_CR86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR et al (2013) Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol 20:5\u201315","journal-title":"Eur J Neurol"},{"key":"2813_CR87","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha J-F et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154\u2013165","journal-title":"Lancet Neurol"},{"key":"2813_CR88","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mds.26139","volume":"30","author":"T Fieblinger","year":"2015","unstructured":"Fieblinger T, Cenci MA (2015) Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. Mov Disord Off J Mov Disord Soc 30:484\u2013493","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR89","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1523\/JNEUROSCI.2702-13.2014","volume":"34","author":"T Fieblinger","year":"2014","unstructured":"Fieblinger T, Sebastianutto I, Alcacer C et al (2014) Mechanisms of dopamine D1 receptor-mediated ERK1\/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J Neurosci 34:4728\u20134740","journal-title":"J Neurosci"},{"key":"2813_CR90","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1126\/science.1077349","volume":"299","author":"CD Fiorillo","year":"2003","unstructured":"Fiorillo CD, Tobler PN, Schultz W (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299:1898\u20131902","journal-title":"Science"},{"key":"2813_CR91","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1089\/ars.2009.2654","volume":"11","author":"KM Fitzpatrick","year":"2009","unstructured":"Fitzpatrick KM, Raschke J, Emborg ME (2009) Cell-based therapies for Parkinson\u2019s disease: past, present, and future. Antioxid Redox Signal 11:2189\u20132208","journal-title":"Antioxid Redox Signal"},{"key":"2813_CR92","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"KA Follett","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 362:2077\u20132091","journal-title":"N Engl J Med"},{"key":"2813_CR93","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.22473","volume":"24","author":"SH Fox","year":"2009","unstructured":"Fox SH, Chuang R, Brotchie JM (2009) Serotonin and Parkinson\u2019s disease: on movement, mood, and madness. Mov Disord Off J Mov Disord Soc 24:1255\u20131266","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR94","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed CR, Greene PE, Breeze RE et al (2001) Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med 344:710\u2013719","journal-title":"N Engl J Med"},{"key":"2813_CR95","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2217\/nmt-2016-0005","volume":"6","author":"ME Freitas","year":"2016","unstructured":"Freitas ME, Fox SH (2016) Nondopaminergic treatments for Parkinson\u2019s disease: current and future prospects. Neurodegener Dis Manag 6:249\u2013268","journal-title":"Neurodegener Dis Manag"},{"key":"2813_CR96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1113\/jphysiol.1911.sp001481","volume":"43","author":"C Funk","year":"1911","unstructured":"Funk C (1911) On the chemical nature of the substance which cures polyneuritis in birds induced by a diet of polished rice. J Physiol 43:395\u2013400","journal-title":"J Physiol"},{"key":"2813_CR97","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1460-9568.1995.tb01092.x","volume":"7","author":"P Gaspar","year":"1995","unstructured":"Gaspar P, Bloch B, Le Moine C (1995) D1 and D2 receptor gene expression in the rat frontal cortex: cellular localization in different classes of efferent neurons. Eur J Neurosci 7:1050\u20131063","journal-title":"Eur J Neurosci"},{"key":"2813_CR98","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S1471-1931(00)00019-7","volume":"23","author":"CR Gerfen","year":"2000","unstructured":"Gerfen CR (2000) Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23:S64\u2013S70","journal-title":"Trends Neurosci"},{"key":"2813_CR99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","volume":"34","author":"CR Gerfen","year":"2011","unstructured":"Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441\u2013466","journal-title":"Annu Rev Neurosci"},{"key":"2813_CR100","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.2147780","volume":"250","author":"CR Gerfen","year":"1990","unstructured":"Gerfen CR, Engber TM, Mahan LC et al (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429\u20131432","journal-title":"Science"},{"key":"2813_CR101","doi-asserted-by":"publisher","first-page":"8167","DOI":"10.1523\/JNEUROSCI.15-12-08167.1995","volume":"15","author":"CR Gerfen","year":"1995","unstructured":"Gerfen CR, Keefe KA, Gauda EB (1995) D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J Neurosci 15:8167\u20138176","journal-title":"J Neurosci"},{"key":"2813_CR102","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1523\/JNEUROSCI.22-12-05042.2002","volume":"22","author":"CR Gerfen","year":"2002","unstructured":"Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1\/2\/MAP kinase. J Neurosci 22:5042\u20135054","journal-title":"J Neurosci"},{"key":"2813_CR103","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mds.26050","volume":"30","author":"OS Gershanik","year":"2015","unstructured":"Gershanik OS (2015) Improving L-dopa therapy: the development of enzyme inhibitors. Mov Disord Off J Mov Disord Soc 30:103\u2013113","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR104","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM198902093200601","volume":"320","author":"CG Goetz","year":"1989","unstructured":"Goetz CG, Olanow CW, Koller WC et al (1989) Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson\u2019s disease. N Engl J Med 320:337\u2013341","journal-title":"N Engl J Med"},{"key":"2813_CR105","doi-asserted-by":"publisher","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","volume":"27","author":"SJ Gold","year":"2007","unstructured":"Gold SJ, Hoang CV, Potts BW et al (2007) RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson\u2019s disease. J Neurosci 27:14338\u201314348","journal-title":"J Neurosci"},{"key":"2813_CR106","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40263-015-0306-3","volume":"30","author":"SL Greig","year":"2016","unstructured":"Greig SL, McKeage K (2016) Carbidopa\/levodopa ER capsules (Rytary(\u00ae), NumientTM): a review in Parkinson\u2019s disease. CNS Drugs 30:79\u201390","journal-title":"CNS Drugs"},{"key":"2813_CR107","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ana.410310611","volume":"31","author":"M Guttman","year":"1992","unstructured":"Guttman M, L\u00e9ger G, Cedarbaum JM et al (1992) 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 31:638\u2013643","journal-title":"Ann Neurol"},{"key":"2813_CR108","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1523\/JNEUROSCI.23-26-08931.2003","volume":"23","author":"JN Guzm\u00e1n","year":"2003","unstructured":"Guzm\u00e1n JN, Hern\u00e1ndez A, Galarraga E et al (2003) Dopaminergic modulation of axon collaterals interconnecting spiny neurons of the rat striatum. J Neurosci 23:8931\u20138940","journal-title":"J Neurosci"},{"key":"2813_CR109","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1471-4159.2005.03558.x","volume":"96","author":"K H\u00e5kansson","year":"2006","unstructured":"H\u00e5kansson K, Galdi S, Hendrick J et al (2006) Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem 96:482\u2013488","journal-title":"J Neurochem"},{"key":"2813_CR110","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1523\/JNEUROSCI.0792-06.2006","volume":"26","author":"PJ Hallett","year":"2006","unstructured":"Hallett PJ, Spoelgen R, Hyman BT et al (2006) Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci 26:4690\u20134700","journal-title":"J Neurosci"},{"key":"2813_CR111","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1471-4159.1996.66020501.x","volume":"66","author":"SK Han","year":"1996","unstructured":"Han SK, Mytilineou C, Cohen G (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66:501\u2013510","journal-title":"J Neurochem"},{"key":"2813_CR112","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.1523\/JNEUROSCI.15-09-06157.1995","volume":"15","author":"DG Harden","year":"1995","unstructured":"Harden DG, Grace AA (1995) Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment. J Neurosci 15:6157\u20136166","journal-title":"J Neurosci"},{"key":"2813_CR113","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/mds.10226","volume":"17","author":"RA Hauser","year":"2002","unstructured":"Hauser RA, Holford NHG (2002) Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 17:961\u2013968","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR114","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1002\/mds.23317","volume":"25","author":"RA Hauser","year":"2010","unstructured":"Hauser RA, Schapira AHV, Rascol O et al (2010) Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 25:2542\u20132549","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR115","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","volume":"10","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Cantillon M, Pourcher E et al (2011) Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221\u2013229","journal-title":"Lancet Neurol"},{"key":"2813_CR116","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser RA, Stocchi F, Rascol O et al (2015) Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72:1491\u20131500","journal-title":"JAMA Neurol"},{"key":"2813_CR117","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0006-8993(81)90840-4","volume":"225","author":"F Hefti","year":"1981","unstructured":"Hefti F, Melamed E (1981) Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry. Brain Res 225:333\u2013346","journal-title":"Brain Res"},{"key":"2813_CR118","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1073\/pnas.1401819111","volume":"111","author":"M Heiman","year":"2014","unstructured":"Heiman M, Heilbut A, Francardo V et al (2014) Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A 111:4578\u20134583","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2813_CR119","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp.67.3.300","volume":"67","author":"MA Hely","year":"1999","unstructured":"Hely MA, Morris JG, Traficante R et al (1999) The Sydney multicentre study of Parkinson\u2019s disease: progression and mortality at 10\u00a0years. J Neurol Neurosurg Psychiatry 67:300\u2013307","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR120","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nn.2592","volume":"13","author":"MJ Higley","year":"2010","unstructured":"Higley MJ, Sabatini BL (2010) Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13:958\u2013966","journal-title":"Nat Neurosci"},{"key":"2813_CR121","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12640-014-9504-x","volume":"27","author":"J Hoenicka","year":"2015","unstructured":"Hoenicka J, Garc\u00eda-Ruiz PJ, Ponce G et al (2015) The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. Neurotox Res 27:205\u2013208","journal-title":"Neurotox Res"},{"key":"2813_CR122","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1476-5381.1958.tb00197.x","volume":"13","author":"O Hornykiewicz","year":"1958","unstructured":"Hornykiewicz O (1958) The action of dopamine on the arterial blood pressure of the guinea-pig. Br J Pharmacol Chemother 13:91\u201394","journal-title":"Br J Pharmacol Chemother"},{"key":"2813_CR123","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","volume":"18","author":"O Hornykiewicz","year":"1966","unstructured":"Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18:925\u2013964","journal-title":"Pharmacol Rev"},{"key":"2813_CR124","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1515\/REVNEURO.2001.12.1.51","volume":"12","author":"CC Huang","year":"2001","unstructured":"Huang CC, Hsu KS (2001) Progress in understanding the factors regulating reversibility of long-term potentiation. Rev Neurosci 12:51\u201368","journal-title":"Rev Neurosci"},{"key":"2813_CR125","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB et al (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Pharmacol Rev 65:171\u2013222","journal-title":"Pharmacol Rev"},{"key":"2813_CR126","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0169-328X(01)00022-5","volume":"87","author":"MJ Hurley","year":"2001","unstructured":"Hurley MJ, Mash DC, Jenner P (2001) Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson\u2019s disease. Brain Res Mol Brain Res 87:271\u2013279","journal-title":"Brain Res Mol Brain Res"},{"key":"2813_CR127","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.2042-7158.1987.tb03413.x","volume":"39","author":"K Iwamoto","year":"1987","unstructured":"Iwamoto K, Watanabe J, Yamada M et al (1987) Effect of age on gastrointestinal and hepatic first-pass effects of levodopa in rats. J Pharm Pharmacol 39:421\u2013425","journal-title":"J Pharm Pharmacol"},{"key":"2813_CR128","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mds.23795","volume":"27","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA (2012) Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts. Mov Disord Off J Mov Disord Soc 27:8\u201330","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR129","first-page":"559","volume":"108","author":"N Jonkers","year":"2001","unstructured":"Jonkers N, Sarre S, Ebinger G, Michotte Y (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm Vienna Austria 1996 108:559\u2013570","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"2813_CR130","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/jnnp.52.6.718","volume":"52","author":"PA Kempster","year":"1989","unstructured":"Kempster PA, Frankel JP, Bovingdon M et al (1989) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 52:718\u2013723","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR131","unstructured":"Kieburtz K, Olanow CW, Cohen Y, Oren S (2016) A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa\/carbidopa (ND0612H) infusion regimens in fluctuating PD patients [abstract]. Mov Disord 31(suppl 2). http:\/\/www.mdsabstracts.org\/abstract\/a-randomized-controlled-clinical-study-to-evaluate-efficacy-safety-and-tolerability-of-sc-l-dopacarbidopa-nd0612h-infusion-regimens-in-fluctuating-pd-patients\/ . Accessed 5 Feb 2018"},{"key":"2813_CR132","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/jnnp-2012-304475","volume":"84","author":"S Klebe","year":"2013","unstructured":"Klebe S, Golmard J-L, Nalls MA et al (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson\u2019s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 84:666\u2013673","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR133","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","volume":"53","author":"WC Koller","year":"1999","unstructured":"Koller WC, Hutton JT, Tolosa E, Capilldeo R (1999) Immediate-release and controlled-release carbidopa\/levodopa in PD: a 5-year randomized multicenter study. Carbidopa\/Levodopa Study Group. Neurology 53:1012\u20131019","journal-title":"Neurology"},{"key":"2813_CR134","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","volume":"38","author":"T Kondo","year":"2015","unstructured":"Kondo T, Mizuno Y, Japanese Istradefylline Study Group (2015) A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol 38:41\u201346","journal-title":"Clin Neuropharmacol"},{"key":"2813_CR135","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","volume":"41","author":"V Kostic","year":"1991","unstructured":"Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson\u2019s disease. Neurology 41:202\u2013205","journal-title":"Neurology"},{"key":"2813_CR136","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0896-6273(02)00859-0","volume":"35","author":"SA Kotecha","year":"2002","unstructured":"Kotecha SA, Oak JN, Jackson MF et al (2002) A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 35:1111\u20131122","journal-title":"Neuron"},{"key":"2813_CR137","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","volume":"87","author":"J Kraemmer","year":"2016","unstructured":"Kraemmer J, Smith K, Weintraub D et al (2016) Clinical-genetic model predicts incident impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 87:1106\u20131111","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR138","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0896-6273(03)00645-7","volume":"40","author":"G Krapivinsky","year":"2003","unstructured":"Krapivinsky G, Krapivinsky L, Manasian Y et al (2003) The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron 40:775\u2013784","journal-title":"Neuron"},{"key":"2813_CR139","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nature09159","volume":"466","author":"AV Kravitz","year":"2010","unstructured":"Kravitz AV, Freeze BS, Parker PRL et al (2010) Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466:622\u2013626","journal-title":"Nature"},{"key":"2813_CR140","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nature05506","volume":"445","author":"AC Kreitzer","year":"2007","unstructured":"Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson\u2019s disease models. Nature 445:643\u2013647","journal-title":"Nature"},{"key":"2813_CR141","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2016.06.005","volume":"30","author":"S Krishnamoorthy","year":"2016","unstructured":"Krishnamoorthy S, Rajan R, Banerjee M et al (2016) Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson\u2019s disease patients. Parkinsonism Relat Disord 30:13\u201317","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR142","first-page":"635","volume":"15","author":"Y Kumakura","year":"2009","unstructured":"Kumakura Y, Cumming P (2009) PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 15:635\u2013650","journal-title":"Neurosci Rev J Bringing Neurobiol Neurol Psychiatry"},{"key":"2813_CR143","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3109\/00207454.2013.841685","volume":"126","author":"R Kumar","year":"2016","unstructured":"Kumar R, Hauser RA, Mostillo J et al (2016) Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson\u2019s disease patients. Int J Neurosci 126:20\u201324","journal-title":"Int J Neurosci"},{"key":"2813_CR144","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.neuropharm.2005.04.022","volume":"49","author":"B Foll Le","year":"2005","unstructured":"Le Foll B, Goldberg SR, Sokoloff P (2005) The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525\u2013541","journal-title":"Neuropharmacology"},{"key":"2813_CR145","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nbd.2009.12.027","volume":"38","author":"M Lebel","year":"2010","unstructured":"Lebel M, Chagniel L, Bureau G, Cyr M (2010) Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38:59\u201367","journal-title":"Neurobiol Dis"},{"key":"2813_CR146","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0092-8674(02)00962-5","volume":"111","author":"FJS Lee","year":"2002","unstructured":"Lee FJS, Xue S, Pei L et al (2002a) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111:219\u2013230","journal-title":"Cell"},{"key":"2813_CR147","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1212\/WNL.58.4.564","volume":"58","author":"MS Lee","year":"2002","unstructured":"Lee MS, Kim HS, Cho EK et al (2002b) COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson\u2019s disease. Neurology 58:564\u2013567","journal-title":"Neurology"},{"key":"2813_CR148","doi-asserted-by":"crossref","unstructured":"Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL (2008) Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 23(12):1696\u20131700","DOI":"10.1002\/mds.22190"},{"key":"2813_CR149","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/mds.22678","volume":"24","author":"J-Y Lee","year":"2009","unstructured":"Lee J-Y, Lee EK, Park SS et al (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 24:1803\u20131810","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR150","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.parkreldis.2011.08.009","volume":"18","author":"J-Y Lee","year":"2012","unstructured":"Lee J-Y, Jeon BS, Kim H-J, Park S-S (2012) Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson\u2019s disease. Parkinsonism Relat Disord 18:76\u201378","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR151","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ana.410200212","volume":"20","author":"KL Leenders","year":"1986","unstructured":"Leenders KL, Poewe WH, Palmer AJ et al (1986) Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258\u2013262","journal-title":"Ann Neurol"},{"key":"2813_CR152","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/jnnp.44.11.1020","volume":"44","author":"AJ Lees","year":"1981","unstructured":"Lees AJ, Stern GM (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 44:1020\u20131023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2813_CR153","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","volume":"29","author":"RP Lesser","year":"1979","unstructured":"Lesser RP, Fahn S, Snider SR et al (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29:1253\u20131260","journal-title":"Neurology"},{"key":"2813_CR154","first-page":"S31","volume":"43","author":"PA LeWitt","year":"1993","unstructured":"LeWitt PA (1993) Levodopa therapeutics: new treatment strategies. Neurology 43:S31\u2013S37","journal-title":"Neurology"},{"key":"2813_CR155","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA (2015) Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord Off J Mov Disord Soc 30:64\u201372","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR156","first-page":"45","volume":"39","author":"PA LeWitt","year":"1989","unstructured":"LeWitt PA, Nelson MV, Berchou RC et al (1989) Controlled-release carbidopa\/levodopa (Sinemet 50\/200 CR4): clinical and pharmacokinetic studies. Neurology 39:45\u201353 discussion 59","journal-title":"Neurology"},{"key":"2813_CR157","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Hauser RA, Grosset DG et al (2016) A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 31:1356\u20131365","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR158","doi-asserted-by":"publisher","first-page":"15551","DOI":"10.1523\/JNEUROSCI.3336-09.2009","volume":"29","author":"Y-C Li","year":"2009","unstructured":"Li Y-C, Xi D, Roman J et al (2009) Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 29:15551\u201315563","journal-title":"J Neurosci"},{"key":"2813_CR159","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0140-6736(95)90062-4","volume":"345","author":"P Limousin","year":"1995","unstructured":"Limousin P, Pollak P, Benazzouz A et al (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet Lond Engl 345:91\u201395","journal-title":"Lancet Lond Engl"},{"key":"2813_CR160","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1126\/science.2105529","volume":"247","author":"O Lindvall","year":"1990","unstructured":"Lindvall O, Brundin P, Widner H et al (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson\u2019s disease. Science 247:574\u2013577","journal-title":"Science"},{"key":"2813_CR161","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0022-3565(25)28524-X","volume":"172","author":"VJ Lotti","year":"1970","unstructured":"Lotti VJ, Porter CC (1970) Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. J Pharmacol Exp Ther 172:406\u2013415","journal-title":"J Pharmacol Exp Ther"},{"key":"2813_CR162","first-page":"53","volume":"109","author":"L Lyras","year":"2002","unstructured":"Lyras L, Zeng B-Y, McKenzie G et al (2002) Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm Vienna Austria 1996 109:53\u201367","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"2813_CR163","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJM198704023161402","volume":"316","author":"I Madrazo","year":"1987","unstructured":"Madrazo I, Drucker-Col\u00edn R, D\u00edaz V et al (1987) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson\u2019s disease. N Engl J Med 316:831\u2013834","journal-title":"N Engl J Med"},{"key":"2813_CR164","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2016.12.058","volume":"374","author":"EM Maloney","year":"2017","unstructured":"Maloney EM, Djamshidian A, O\u2019Sullivan SS (2017) Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson\u2019s disease, atypical Parkinsonian disorders and non-Parkinsonian populations. J Neurol Sci 374:47\u201352","journal-title":"J Neurol Sci"},{"key":"2813_CR165","first-page":"291","volume":"39","author":"PT M\u00e4nnist\u00f6","year":"1992","unstructured":"M\u00e4nnist\u00f6 PT, Ulmanen I, Lundstr\u00f6m K et al (1992) Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res Fortschr Arzneimittelforschung Prog Rech Pharm 39:291\u2013350","journal-title":"Prog Drug Res Fortschr Arzneimittelforschung Prog Rech Pharm"},{"key":"2813_CR166","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mds.25708","volume":"29","author":"S Marrinan","year":"2014","unstructured":"Marrinan S, Emmanuel AV, Burn DJ (2014) Delayed gastric emptying in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 29:23\u201332","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR167","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(77)91146-1","volume":"1","author":"CD Marsden","year":"1977","unstructured":"Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson\u2019s disease. Lancet Lond Engl 1:345\u2013349","journal-title":"Lancet Lond Engl"},{"key":"2813_CR168","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0006-8993(89)91160-8","volume":"493","author":"JF Marshall","year":"1989","unstructured":"Marshall JF, Navarrete R, Joyce JN (1989) Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res 493:247\u2013257","journal-title":"Brain Res"},{"key":"2813_CR169","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.21586","volume":"22","author":"P Martinez-Martin","year":"2007","unstructured":"Martinez-Martin P, Schapira AHV, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson\u2019s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord Off J Mov Disord Soc 22:1623\u20131629","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR170","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM et al (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 26:399\u2013406","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR171","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2004.10.002","volume":"11","author":"L Mazzella","year":"2005","unstructured":"Mazzella L, Yahr MD, Marinelli L et al (2005) Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson\u2019s disease on L-dopa monotherapy. Parkinsonism Relat Disord 11:151\u2013155","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR172","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"J Meiser","year":"2013","unstructured":"Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11:34","journal-title":"Cell Commun Signal"},{"key":"2813_CR173","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","volume":"101","author":"F Mela","year":"2007","unstructured":"Mela F, Marti M, Dekundy A et al (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson\u2019s disease. J Neurochem 101:483\u2013497","journal-title":"J Neurochem"},{"key":"2813_CR174","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1056\/NEJM197501232920404","volume":"292","author":"I Mena","year":"1975","unstructured":"Mena I, Cotzias GC (1975) Protein intake and treatment of Parkinson\u2019s disease with levodopa. N Engl J Med 292:181\u2013184","journal-title":"N Engl J Med"},{"key":"2813_CR175","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mds.870070105","volume":"7","author":"MA Mena","year":"1992","unstructured":"Mena MA, Pardo B, Casarejos MJ et al (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord Off J Mov Disord Soc 7:23\u201331","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR176","first-page":"125","volume":"7","author":"M Menegoz","year":"1995","unstructured":"Menegoz M, Lau LF, Herv\u00e9 D et al (1995) Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 7:125\u2013128","journal-title":"Neuroreport"},{"key":"2813_CR177","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/00002826-199712000-00004","volume":"20","author":"E Miyawaki","year":"1997","unstructured":"Miyawaki E, Lyons K, Pahwa R et al (1997) Motor complications of chronic levodopa therapy in Parkinson\u2019s disease. Clin Neuropharmacol 20:523\u2013530","journal-title":"Clin Neuropharmacol"},{"key":"2813_CR178","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.25418","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno Y, Kondo T, Japanese Istradefylline Study Group (2013) Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 28:1138\u20131141","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR179","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/180244a0","volume":"180","author":"KA Montagu","year":"1957","unstructured":"Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180:244\u2013245","journal-title":"Nature"},{"key":"2813_CR180","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/brain\/awv063","volume":"138","author":"C Moreau","year":"2015","unstructured":"Moreau C, Meguig S, Corvol J-C et al (2015) Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson\u2019s disease. Brain J Neurol 138:1271\u20131283","journal-title":"Brain J Neurol"},{"key":"2813_CR181","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","volume":"49","author":"M Morissette","year":"1997","unstructured":"Morissette M, Goulet M, Soghomonian JJ et al (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49:55\u201362","journal-title":"Brain Res Mol Brain Res"},{"key":"2813_CR182","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26103","volume":"30","author":"EV Mosharov","year":"2015","unstructured":"Mosharov EV, Borgkvist A, Sulzer D (2015) Presynaptic effects of levodopa and their possible role in dyskinesia. Mov Disord Off J Mov Disord Soc 30:45\u201353","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR183","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ana.410220406","volume":"22","author":"MM Mouradian","year":"1987","unstructured":"Mouradian MM, Juncos JL, Fabbrini G, Chase TN (1987) Motor fluctuations in Parkinson\u2019s disease: pathogenetic and therapeutic studies. Ann Neurol 22:475\u2013479","journal-title":"Ann Neurol"},{"key":"2813_CR184","first-page":"231","volume":"46","author":"MD Muenter","year":"1971","unstructured":"Muenter MD, Tyce GM (1971) L-dopa therapy of Parkinson\u2019s disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46:231\u2013239","journal-title":"Mayo Clin Proc"},{"key":"2813_CR185","first-page":"1177","volume":"103","author":"M Murata","year":"1996","unstructured":"Murata M, Mizusawa H, Yamanouchi H, Kanazawa I (1996) Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm Vienna Austria 1996 103:1177\u20131185","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"2813_CR186","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.410430504","volume":"43","author":"MG Murer","year":"1998","unstructured":"Murer MG, Dziewczapolski G, Menalled LB et al (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43:561\u2013575","journal-title":"Ann Neurol"},{"key":"2813_CR187","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/j.1471-4159.1993.tb13642.x","volume":"61","author":"C Mytilineou","year":"1993","unstructured":"Mytilineou C, Han SK, Cohen G (1993) Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61:1470\u20131478","journal-title":"J Neurochem"},{"key":"2813_CR188","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/jpet.102.042267","volume":"304","author":"C Mytilineou","year":"2003","unstructured":"Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304:792\u2013800","journal-title":"J Pharmacol Exp Ther"},{"key":"2813_CR189","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1042\/bj20030017","volume":"373","author":"VD Nair","year":"2003","unstructured":"Nair VD, Olanow CW, Sealfon SC (2003) Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373:25\u201332","journal-title":"Biochem J"},{"key":"2813_CR190","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.170.3953.76","volume":"170","author":"KY Ng","year":"1970","unstructured":"Ng KY, Chase TN, Colburn RW, Kopin IJ (1970) L-Dopa-induced release of cerebral monoamines. Science 170:76\u201377","journal-title":"Science"},{"key":"2813_CR191","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/230331a0","volume":"230","author":"KY Ng","year":"1971","unstructured":"Ng KY, Colburn RW, Kopin IJ (1971) Effects of L-dopa on efflux of cerebral monoamines from synaptosomes. Nature 230:331\u2013332","journal-title":"Nature"},{"key":"2813_CR192","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.410220415","volume":"22","author":"JG Nutt","year":"1987","unstructured":"Nutt JG (1987) On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22:535\u2013540","journal-title":"Ann Neurol"},{"key":"2813_CR193","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.410390504","volume":"39","author":"JG Nutt","year":"1996","unstructured":"Nutt JG, Holford NH (1996) The response to levodopa in Parkinson\u2019s disease: imposing pharmacological law and order. Ann Neurol 39:561\u2013573","journal-title":"Ann Neurol"},{"key":"2813_CR194","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Woodward WR, Hammerstad JP et al (1984) The \u201con-off\u201d phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N Engl J Med 310:483\u2013488","journal-title":"N Engl J Med"},{"key":"2813_CR195","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.410180505","volume":"18","author":"JG Nutt","year":"1985","unstructured":"Nutt JG, Woodward WR, Anderson JL (1985) The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 18:537\u2013543","journal-title":"Ann Neurol"},{"key":"2813_CR196","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mds.870120304","volume":"12","author":"JG Nutt","year":"1997","unstructured":"Nutt JG, Carter JH, Lea ES, Woodward WR (1997) Motor fluctuations during continuous levodopa infusions in patients with Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 12:285\u2013292","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR197","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ana.10189","volume":"51","author":"JG Nutt","year":"2002","unstructured":"Nutt JG, Carter JH, Lea ES, Sexton GJ (2002) Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 51:686\u2013693","journal-title":"Ann Neurol"},{"key":"2813_CR198","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm D (2006) Pharmacokinetic optimisation in the treatment of Parkinson\u2019s disease : an update. Clin Pharmacokinet 45:109\u2013136","journal-title":"Clin Pharmacokinet"},{"key":"2813_CR199","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.4.2.193","volume":"4","author":"D Nyholm","year":"2008","unstructured":"Nyholm D, Lennern\u00e4s H (2008) Irregular gastrointestinal drug absorption in Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 4:193\u2013203","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"2813_CR200","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/mds.870040510","volume":"4","author":"JA Obeso","year":"1989","unstructured":"Obeso JA, Vaamonde J, Grandas F et al (1989) Overcoming pharmacokinetic problems in the treatment of Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 4(Suppl 1):S70\u2013S85","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR201","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mds.20724","volume":"21","author":"WH Oertel","year":"2006","unstructured":"Oertel WH, Wolters E, Sampaio C et al (2006) Pergolide versus levodopa monotherapy in early Parkinson\u2019s disease patients: the PELMOPET study. Mov Disord Off J Mov Disord Soc 21:343\u2013353","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR202","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0022-510X(84)90003-0","volume":"66","author":"S Ogasahara","year":"1984","unstructured":"Ogasahara S, Nishikawa Y, Takahashi M et al (1984) Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease. J Neurol Sci 66:151\u2013163","journal-title":"J Neurol Sci"},{"key":"2813_CR203","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0006-8993(98)01049-X","volume":"813","author":"JD Oh","year":"1998","unstructured":"Oh JD, Russell DS, Vaughan CL et al (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 813:150\u2013159","journal-title":"Brain Res"},{"key":"2813_CR204","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.26119","volume":"30","author":"CW Olanow","year":"2015","unstructured":"Olanow CW (2015) Levodopa: effect on cell death and the natural history of Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 30:37\u201344","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR205","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow CW, Goetz CG, Kordower JH et al (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann Neurol 54:403\u2013414","journal-title":"Ann Neurol"},{"key":"2813_CR206","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5:677\u2013687","journal-title":"Lancet Neurol"},{"key":"2813_CR207","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 361:1268\u20131278","journal-title":"N Engl J Med"},{"key":"2813_CR208","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149","journal-title":"Lancet Neurol"},{"key":"2813_CR209","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-0404.1991.tb05021.x","volume":"136","author":"L Oreland","year":"1991","unstructured":"Oreland L (1991) Monoamine oxidase, dopamine and Parkinson\u2019s disease. Acta Neurol Scand Suppl 136:60\u201365","journal-title":"Acta Neurol Scand Suppl"},{"key":"2813_CR210","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","volume":"82","author":"F Ory-Magne","year":"2014","unstructured":"Ory-Magne F, Corvol J-C, Azulay J-P et al (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82:300\u2013307","journal-title":"Neurology"},{"key":"2813_CR211","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Tanner CM, Hauser RA et al (2017) ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol 74:941\u2013949","journal-title":"JAMA Neurol"},{"key":"2813_CR212","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi S, Gurruchaga JM, Ralph GS et al (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet Lond Engl 383:1138\u20131146","journal-title":"Lancet Lond Engl"},{"key":"2813_CR213","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/WNL.51.2.520","volume":"51","author":"S P\u00e5lhagen","year":"1998","unstructured":"P\u00e5lhagen S, Heinonen EH, H\u00e4gglund J et al (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 51:520\u2013525","journal-title":"Neurology"},{"key":"2813_CR214","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","volume":"83","author":"K Papay","year":"2014","unstructured":"Papay K, Xie SX, Stern M et al (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83:826\u2013833","journal-title":"Neurology"},{"key":"2813_CR215","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mds.870080305","volume":"8","author":"B Pardo","year":"1993","unstructured":"Pardo B, Mena MA, Fahn S, Garc\u00eda de Y\u00e9benes J (1993) Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord Off J Mov Disord Soc 8:278\u2013284","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"10","key":"2813_CR216","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989) DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch Neurol 46(10):1052\u20131060","journal-title":"Arch Neurol"},{"key":"2813_CR217","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284:1931\u20131938","journal-title":"JAMA"},{"key":"2813_CR218","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653\u20131661","journal-title":"JAMA"},{"key":"2813_CR219","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1212\/WNL.0b013e318232ab4c","volume":"77","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen L, O\u2019Sullivan SS, Kuoppam\u00e4ki M et al (2011) Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 77:1420\u20131426","journal-title":"Neurology"},{"key":"2813_CR220","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.biopsych.2010.08.031","volume":"69","author":"V Pascoli","year":"2011","unstructured":"Pascoli V, Besnard A, Herv\u00e9 D et al (2011) Cyclic adenosine monophosphate-independent tyrosine phosphorylation of NR2B mediates cocaine-induced extracellular signal-regulated kinase activation. Biol Psychiatry 69:218\u2013227","journal-title":"Biol Psychiatry"},{"key":"2813_CR221","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","volume":"59","author":"N Pav\u00f3n","year":"2006","unstructured":"Pav\u00f3n N, Mart\u00edn AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64\u201374","journal-title":"Biol Psychiatry"},{"key":"2813_CR222","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1471-4159.1984.tb12834.x","volume":"43","author":"TL Perry","year":"1984","unstructured":"Perry TL, Yong VW, Ito M et al (1984) Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 43:990\u2013993","journal-title":"J Neurochem"},{"key":"2813_CR223","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1073\/pnas.97.16.9226","volume":"97","author":"ME Phelps","year":"2000","unstructured":"Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97:9226\u20139233","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2813_CR224","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn1040","volume":"6","author":"B Picconi","year":"2003","unstructured":"Picconi B, Centonze D, H\u00e5kansson K et al (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501\u2013506","journal-title":"Nat Neurosci"},{"key":"2813_CR225","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/j.1471-4159.1992.tb10939.x","volume":"58","author":"C Pifl","year":"1992","unstructured":"Pifl C, Nanoff C, Schingnitz G et al (1992) Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson\u2019s disease. J Neurochem 58:1997\u20132004","journal-title":"J Neurochem"},{"key":"2813_CR226","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/14740338.2015.988137","volume":"14","author":"M Pilleri","year":"2015","unstructured":"Pilleri M, Antonini A (2015) Therapeutic strategies to prevent and manage dyskinesias in Parkinson\u2019s disease. Expert Opin Drug Saf 14:281\u2013294","journal-title":"Expert Opin Drug Saf"},{"key":"2813_CR227","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","volume":"277","author":"M Politis","year":"2015","unstructured":"Politis M, Niccolini F (2015) Serotonin in Parkinson\u2019s disease. Behav Brain Res 277:136\u2013145","journal-title":"Behav Brain Res"},{"key":"2813_CR228","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","volume":"79","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Lang AE, Munhoz RP et al (2012) Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79:651\u2013658","journal-title":"Neurology"},{"key":"2813_CR229","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/mds.870100107","volume":"10","author":"S Przedborski","year":"1995","unstructured":"Przedborski S, Levivier M, Raftopoulos C et al (1995) Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord Off J Mov Disord Soc 10:28\u201336","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR230","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1212\/WNL.34.9.1131","volume":"34","author":"N Quinn","year":"1984","unstructured":"Quinn N, Parkes JD, Marsden CD (1984) Control of on\/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131\u20131136","journal-title":"Neurology"},{"key":"2813_CR231","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nbd.2010.08.018","volume":"41","author":"C Rangel-Barajas","year":"2011","unstructured":"Rangel-Barajas C, Silva I, Lop\u00e9z-Santiago LM et al (2011) L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V\/VI and increased GABA release in the substantia nigra reticulata. Neurobiol Dis 41:51\u201361","journal-title":"Neurobiol Dis"},{"key":"2813_CR232","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1517\/14656560902746041","volume":"10","author":"O Rascol","year":"2009","unstructured":"Rascol O, Perez-Lloret S (2009) Rotigotine transdermal delivery for the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother 10:677\u2013691","journal-title":"Expert Opin Pharmacother"},{"key":"2813_CR233","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"2813_CR234","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet Lond Engl 365:947\u2013954","journal-title":"Lancet Lond Engl"},{"key":"2813_CR235","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mds.26362","volume":"30","author":"O Rascol","year":"2015","unstructured":"Rascol O, Perez-Lloret S, Ferreira JJ (2015) New treatments for levodopa-induced motor complications. Mov Disord Off J Mov Disord Soc 30:1451\u20131460","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR236","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1212\/WNL.32.6.684","volume":"32","author":"A Reches","year":"1982","unstructured":"Reches A, Fahn S, Bhawan J (1982) Chronic dopa feeding of mice. Neurology 32:684\u2013685","journal-title":"Neurology"},{"key":"2813_CR237","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WNF.0b013e31815d25ce","volume":"31","author":"I Rektorova","year":"2008","unstructured":"Rektorova I, Balaz M, Svatova J et al (2008) Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 31:261\u2013266","journal-title":"Clin Neuropharmacol"},{"key":"2813_CR238","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbr.2012.04.027","volume":"233","author":"JL Riddle","year":"2012","unstructured":"Riddle JL, Rokosik SL, Napier TC (2012) Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson\u2019s disease and controls. Behav Brain Res 233:15\u201323","journal-title":"Behav Brain Res"},{"key":"2813_CR239","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","volume":"55 Suppl 1","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Bracco F, Chouza C et al (1998) Early treatment of Parkinson\u2019s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 Suppl 1:23\u201330","journal-title":"Drugs"},{"key":"2813_CR240","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1046\/j.1460-9568.2002.02280.x","volume":"16","author":"A Rivera","year":"2002","unstructured":"Rivera A, Alberti I, Mart\u00edn AB et al (2002) Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. Eur J Neurosci 16:2049\u20132058","journal-title":"Eur J Neurosci"},{"key":"2813_CR241","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2125.1989.tb03506.x","volume":"28","author":"DR Robertson","year":"1989","unstructured":"Robertson DR, Wood ND, Everest H et al (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28:61\u201369","journal-title":"Br J Clin Pharmacol"},{"key":"2813_CR242","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2125.1990.tb03601.x","volume":"29","author":"DR Robertson","year":"1990","unstructured":"Robertson DR, Renwick AG, Wood ND et al (1990a) The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 29:47\u201353","journal-title":"Br J Clin Pharmacol"},{"key":"2813_CR243","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/0006-8993(90)91498-6","volume":"523","author":"GS Robertson","year":"1990","unstructured":"Robertson GS, Vincent SR, Fibiger HC (1990b) Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain Res 523:288\u2013290","journal-title":"Brain Res"},{"key":"2813_CR244","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF00280127","volume":"42","author":"DR Robertson","year":"1992","unstructured":"Robertson DR, Renwick AG, Macklin B et al (1992) The influence of levodopa on gastric emptying in healthy elderly volunteers. Eur J Clin Pharmacol 42:409\u2013412","journal-title":"Eur J Clin Pharmacol"},{"key":"2813_CR245","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0896-6273(00)80144-0","volume":"16","author":"KW Roche","year":"1996","unstructured":"Roche KW, O\u2019Brien RJ, Mammen AL et al (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179\u20131188","journal-title":"Neuron"},{"key":"2813_CR246","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/mds.26197","volume":"30","author":"I Ruiz-DeDiego","year":"2015","unstructured":"Ruiz-DeDiego I, Naranjo JR, Herv\u00e9 D, Moratalla R (2015) Dopaminergic regulation of olfactory type G-protein \u03b1 subunit expression in the striatum. Mov Disord Off J Mov Disord Soc 30:1039\u20131049","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR247","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1124\/jpet.108.150425","volume":"330","author":"D Rylander","year":"2009","unstructured":"Rylander D, Recchia A, Mela F et al (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330:227\u2013235","journal-title":"J Pharmacol Exp Ther"},{"key":"2813_CR248","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","volume":"27","author":"E Santini","year":"2007","unstructured":"Santini E, Valjent E, Usiello A et al (2007) Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27:6995\u20137005","journal-title":"J Neurosci"},{"key":"2813_CR249","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1471-4159.2008.05831.x","volume":"108","author":"E Santini","year":"2009","unstructured":"Santini E, Alcacer C, Cacciatore S et al (2009) L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108:621\u2013633","journal-title":"J Neurochem"},{"key":"2813_CR250","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012322","volume":"5","author":"E Santini","year":"2010","unstructured":"Santini E, Sgambato-Faure V, Li Q et al (2010) Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One 5:e12322","journal-title":"PLoS One"},{"key":"2813_CR251","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jps.2600701018","volume":"70","author":"K Sasahara","year":"1981","unstructured":"Sasahara K, Nitanai T, Habara T et al (1981) Dosage form design for improvement of bioavailability of levodopa V: absorption and metabolism of levodopa in intestinal segments of dogs. J Pharm Sci 70:1157\u20131160","journal-title":"J Pharm Sci"},{"key":"2813_CR252","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1212\/WNL.58.suppl_1.S9","volume":"58","author":"AHV Schapira","year":"2002","unstructured":"Schapira AHV (2002) Neuroprotection and dopamine agonists. Neurology 58:S9\u201318","journal-title":"Neurology"},{"issue":"Pt 11","key":"2813_CR253","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain J Neurol 123(Pt 11):2297\u20132305","journal-title":"Brain J Neurol"},{"key":"2813_CR254","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WMM Schuepbach","year":"2013","unstructured":"Schuepbach WMM, Rau J, Knudsen K et al (2013) Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med 368:610\u2013622","journal-title":"N Engl J Med"},{"key":"2813_CR255","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.neuro.28.061604.135722","volume":"30","author":"W Schultz","year":"2007","unstructured":"Schultz W (2007) Multiple dopamine functions at different time courses. Annu Rev Neurosci 30:259\u2013288","journal-title":"Annu Rev Neurosci"},{"key":"2813_CR256","first-page":"251","volume":"56","author":"RS Schwab","year":"1951","unstructured":"Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson\u2019s disease. Trans Am Neurol Assoc 56:251\u2013253","journal-title":"Trans Am Neurol Assoc"},{"key":"2813_CR257","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P (2015) Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183\u2013189","journal-title":"Synapse"},{"key":"2813_CR258","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M et al (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 26:S42\u2013S80","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR259","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1146\/annurev.cellbio.23.090506.123516","volume":"23","author":"JD Shepherd","year":"2007","unstructured":"Shepherd JD, Huganir RL (2007) The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 23:613\u2013643","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2813_CR260","first-page":"488","volume":"60","author":"H Shinotoh","year":"1993","unstructured":"Shinotoh H, Hirayama K, Tateno Y (1993) Dopamine D1 and D2 receptors in Parkinson\u2019s disease and striatonigral degeneration determined by PET. Adv Neurol 60:488\u2013493","journal-title":"Adv Neurol"},{"key":"2813_CR261","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0025-7125(05)70113-9","volume":"83","author":"A Siderowf","year":"1999","unstructured":"Siderowf A, Kurlan R (1999) Monoamine oxidase and catechol-O-methyltransferase inhibitors. Med Clin North Am 83:445\u2013467","journal-title":"Med Clin North Am"},{"key":"2813_CR262","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn1664","volume":"9","author":"VA Skeberdis","year":"2006","unstructured":"Skeberdis VA, Chevaleyre V, Lau CG et al (2006) Protein kinase A regulates calcium permeability of NMDA receptors. Nat Neurosci 9:501\u2013510","journal-title":"Nat Neurosci"},{"key":"2813_CR263","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/archgenpsychiatry.2010.51","volume":"67","author":"WS Slutske","year":"2010","unstructured":"Slutske WS, Zhu G, Meier MH, Martin NG (2010) Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry 67:624\u2013630","journal-title":"Arch Gen Psychiatry"},{"key":"2813_CR264","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0166-2236(90)90106-K","volume":"13","author":"AD Smith","year":"1990","unstructured":"Smith AD, Bolam JP (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259\u2013265","journal-title":"Trends Neurosci"},{"key":"2813_CR265","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1523\/JNEUROSCI.20-12-04480.2000","volume":"20","author":"GL Snyder","year":"2000","unstructured":"Snyder GL, Allen PB, Fienberg AA et al (2000) Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J Neurosci 20:4480\u20134488","journal-title":"J Neurosci"},{"key":"2813_CR266","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/ejn.13390","volume":"45","author":"P Sokoloff","year":"2017","unstructured":"Sokoloff P, Le Foll B (2017) The dopamine D3 receptor, a quarter century later. Eur J Neurosci 45:2\u201319","journal-title":"Eur J Neurosci"},{"key":"2813_CR267","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0025-6196(12)64861-7","volume":"63","author":"PA Southorn","year":"1988","unstructured":"Southorn PA, Powis G (1988) Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc 63:381\u2013389","journal-title":"Mayo Clin Proc"},{"key":"2813_CR268","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/(SICI)1096-9861(19961223)376:4<530::AID-CNE3>3.0.CO;2-2","volume":"376","author":"H Steiner","year":"1996","unstructured":"Steiner H, Gerfen CR (1996) Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction. J Comp Neurol 376:530\u2013541","journal-title":"J Comp Neurol"},{"key":"2813_CR269","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1185\/03007990802387130","volume":"24","author":"F Stocchi","year":"2008","unstructured":"Stocchi F, Hersh BP, Scott BL et al (2008) Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson\u2019s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24:2883\u20132895","journal-title":"Curr Med Res Opin"},{"key":"2813_CR270","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/mds.25561","volume":"28","author":"F Stocchi","year":"2013","unstructured":"Stocchi F, Rascol O, Destee A et al (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord Off J Mov Disord Soc 28:1838\u20131846","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR271","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/REVNEURO.2000.11.2-3.159","volume":"11","author":"D Sulzer","year":"2000","unstructured":"Sulzer D, Pothos EN (2000) Regulation of quantal size by presynaptic mechanisms. Rev Neurosci 11:159\u2013212","journal-title":"Rev Neurosci"},{"key":"2813_CR272","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/brain\/awu409","volume":"138","author":"P Svenningsson","year":"2015","unstructured":"Svenningsson P, Rosenblad C, Af Edholm Arvidsson K et al (2015) Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain J Neurol 138:963\u2013973","journal-title":"Brain J Neurol"},{"key":"2813_CR273","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-83-4-456","volume":"83","author":"RD Sweet","year":"1975","unstructured":"Sweet RD, McDowell FH (1975) Five years\u2019 treatment of Parkinson\u2019s disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 83:456\u2013463","journal-title":"Ann Intern Med"},{"key":"2813_CR274","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1212\/WNL.35.6.918","volume":"35","author":"CM Tanner","year":"1985","unstructured":"Tanner CM, Chhablani R, Goetz CG, Klawans HL (1985) Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology 35:918\u2013921","journal-title":"Neurology"},{"key":"2813_CR275","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1152\/jn.00672.2004","volume":"93","author":"S Taverna","year":"2005","unstructured":"Taverna S, Canciani B, Pennartz CMA (2005) Dopamine D1-receptors modulate lateral inhibition between principal cells of the nucleus accumbens. J Neurophysiol 93:1816\u20131819","journal-title":"J Neurophysiol"},{"key":"2813_CR276","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1523\/JNEUROSCI.6145-08.2009","volume":"29","author":"F Tecuapetla","year":"2009","unstructured":"Tecuapetla F, Ko\u00f3s T, Tepper JM et al (2009) Differential dopaminergic modulation of neostriatal synaptic connections of striatopallidal axon collaterals. J Neurosci 29:8977\u20138990","journal-title":"J Neurosci"},{"key":"2813_CR277","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.nbd.2014.08.006","volume":"71","author":"SL Thiele","year":"2014","unstructured":"Thiele SL, Chen B, Lo C et al (2014) Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiol Dis 71:334\u2013344","journal-title":"Neurobiol Dis"},{"key":"2813_CR278","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/mds.26659","volume":"31","author":"F Tison","year":"2016","unstructured":"Tison F, Keywood C, Wakefield M et al (2016) A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 31:1373\u20131380","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR279","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/practneurol-2013-000741","volume":"14","author":"A Todorova","year":"2014","unstructured":"Todorova A, Jenner P, Ray Chaudhuri K (2014) Non-motor Parkinson\u2019s: integral to motor Parkinson\u2019s, yet often neglected. Pract Neurol 14:310\u2013322","journal-title":"Pract Neurol"},{"key":"2813_CR280","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1113\/jphysiol.2008.158931","volume":"586","author":"H Tong","year":"2008","unstructured":"Tong H, Gibb AJ (2008) Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum. J Physiol 586:4693\u20134707","journal-title":"J Physiol"},{"key":"2813_CR281","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ana.10814","volume":"55","author":"J Tong","year":"2004","unstructured":"Tong J, Fitzmaurice PS, Ang LC et al (2004) Brain dopamine-stimulated adenylyl cyclase activity in Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 55:125\u2013129","journal-title":"Ann Neurol"},{"key":"2813_CR282","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00243-4","volume":"14","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Chaudhuri KR, Martinez-Martin P et al (2015) Prolonged-release oxycodone\u2013naloxone for treatment of severe pain in patients with Parkinson\u2019s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 14:1161\u20131170","journal-title":"Lancet Neurol"},{"key":"2813_CR283","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.26569","volume":"31","author":"C Trenkwalder","year":"2016","unstructured":"Trenkwalder C, Berg D, Rascol O et al (2016) A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia. Mov Disord Off J Mov Disord Soc 31:1049\u20131054","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2813_CR284","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neuron.2012.09.023","volume":"76","author":"NX Tritsch","year":"2012","unstructured":"Tritsch NX, Sabatini BL (2012) Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 76:33\u201350","journal-title":"Neuron"},{"key":"2813_CR285","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1212\/WNL.49.3.717","volume":"49","author":"N Turjanski","year":"1997","unstructured":"Turjanski N, Lees AJ, Brooks DJ (1997) In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson\u2019s disease patients with and without dyskinesias. Neurology 49:717\u2013723","journal-title":"Neurology"},{"key":"2813_CR286","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/j.1471-4159.2007.04655.x","volume":"102","author":"B Valastro","year":"2007","unstructured":"Valastro B, Dekundy A, Krogh M et al (2007) Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J Neurochem 102:1395\u20131409","journal-title":"J Neurochem"},{"key":"2813_CR287","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.parkreldis.2011.10.019","volume":"18","author":"A Vallelunga","year":"2012","unstructured":"Vallelunga A, Flaibani R, Formento-Dojot P et al (2012) Role of genetic polymorphisms of the dopaminergic system in Parkinson\u2019s disease patients with impulse control disorders. Parkinsonism Relat Disord 18:397\u2013399","journal-title":"Parkinsonism Relat Disord"},{"key":"2813_CR288","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","volume":"363","author":"G Camp Van","year":"2004","unstructured":"Van Camp G, Flamez A, Cosyns B et al (2004) Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet Lond Engl 363:1179\u20131183","journal-title":"Lancet Lond Engl"},{"key":"2813_CR289","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1001\/archneur.63.2.205","volume":"63","author":"JA Gerpen Van","year":"2006","unstructured":"Van Gerpen JA, Kumar N, Bower JH et al (2006) Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990. Arch Neurol 63:205\u2013209","journal-title":"Arch Neurol"},{"key":"2813_CR290","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P et al (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50:1323\u20131326","journal-title":"Neurology"},{"key":"2813_CR291","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","volume":"76","author":"D Vijayakumar","year":"2016","unstructured":"Vijayakumar D, Jankovic J (2016) Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs 76:759\u2013777","journal-title":"Drugs"},{"key":"2813_CR292","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","volume":"64","author":"V Voon","year":"2007","unstructured":"Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64:1089\u20131096","journal-title":"Arch Neurol"},{"key":"2813_CR293","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuron.2009.12.027","volume":"65","author":"V Voon","year":"2010","unstructured":"Voon V, Pessiglione M, Brezing C et al (2010) Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65:135\u2013142","journal-title":"Neuron"},{"key":"2813_CR294","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/WCO.0b013e3283489687","volume":"24","author":"V Voon","year":"2011","unstructured":"Voon V, Mehta AR, Hallett M (2011) Impulse control disorders in Parkinson\u2019s disease: recent advances. Curr Opin Neurol 24:324\u2013330","journal-title":"Curr Opin Neurol"},{"key":"2813_CR295","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","volume":"16","author":"V Voon","year":"2017","unstructured":"Voon V, Napier TC, Frank MJ et al (2017) Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update. Lancet Neurol 16:238\u2013250","journal-title":"Lancet Neurol"},{"key":"2813_CR296","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/242463a0","volume":"242","author":"DN Wade","year":"1973","unstructured":"Wade DN, Mearrick PT, Morris JL (1973) Active transport of L-dopa in the intestine. Nature 242:463\u2013465","journal-title":"Nature"},{"key":"2813_CR297","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1991.tb03990.x","volume":"32","author":"DG Waller","year":"1991","unstructured":"Waller DG, Usman F, Renwick AG et al (1991) Oral amino acids and gastric emptying: an investigation of the mechanism of levodopa-induced gastric stasis. Br J Clin Pharmacol 32:771\u2013773","journal-title":"Br J Clin Pharmacol"},{"key":"2813_CR298","first-page":"105","volume":"10","author":"Q Wang","year":"2016","unstructured":"Wang Q, Zhang W (2016) Maladaptive synaptic plasticity in L-DOPA-induced dyskinesia. Front Neural Circ 10:105","journal-title":"Front Neural Circ"},{"key":"2813_CR299","doi-asserted-by":"publisher","first-page":"39386","DOI":"10.1074\/jbc.M104981200","volume":"276","author":"Q Wang","year":"2001","unstructured":"Wang Q, Jolly JP, Surmeier JD et al (2001) Differential dependence of the D1 and D5 dopamine receptors on the G protein gamma 7 subunit for activation of adenylylcyclase. J Biol Chem 276:39386\u201339393","journal-title":"J Biol Chem"},{"key":"2813_CR300","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1113\/jphysiol.2012.235200","volume":"590","author":"W Wang","year":"2012","unstructured":"Wang W, Dever D, Lowe J et al (2012) Regulation of prefrontal excitatory neurotransmission by dopamine in the nucleus accumbens core. J Physiol 590:3743\u20133769","journal-title":"J Physiol"},{"key":"2813_CR301","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1212\/WNL.55.1.51","volume":"55","author":"P Watkins","year":"2000","unstructured":"Watkins P (2000) COMT inhibitors and liver toxicity. Neurology 55:S51\u2013S52 discussion S53-56","journal-title":"Neurology"},{"key":"2813_CR302","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/1801050a0","volume":"180","author":"H Weil-Malherbe","year":"1957","unstructured":"Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature 180:1050\u20131051","journal-title":"Nature"},{"key":"2813_CR303","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595","journal-title":"Arch Neurol"},{"key":"2813_CR304","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","volume":"80","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Papay K, Siderowf A, Parkinson\u2019s Progression Markers Initiative (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80:176\u2013180","journal-title":"Neurology"},{"key":"2813_CR305","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","volume":"62","author":"JE Westin","year":"2007","unstructured":"Westin JE, Vercammen L, Strome EM et al (2007) Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62:800\u2013810","journal-title":"Biol Psychiatry"},{"key":"2813_CR306","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessl AJ et al (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93\u2013101","journal-title":"Ann Neurol"},{"key":"2813_CR307","doi-asserted-by":"publisher","unstructured":"Wickens JR, Arbuthnott GW (2005) Chapter IV Structural and functional interactions in the striatum at the receptor level. In: Dunnett SB, Bentivoglio M, Bj\u00f6rklund A, H\u00f6kfelt T (eds) Handbook of chemical neuroanatomy, Dopamine, volume 21. Elsevier, pp 199\u2013236. https:\/\/doi.org\/10.1016\/S0924-8196(05)80008-9","DOI":"10.1016\/S0924-8196(05)80008-9"},{"key":"2813_CR308","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.neurol.2012.06.014","volume":"168","author":"T Witjas","year":"2012","unstructured":"Witjas T, Eusebio A, Fluch\u00e8re F, Azulay J-P (2012) Addictive behaviors and Parkinson\u2019s disease. Rev Neurol (Paris) 168:624\u2013633","journal-title":"Rev Neurol (Paris)"},{"key":"2813_CR309","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ et al (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21:343\u2013354","journal-title":"Arch Neurol"},{"key":"2813_CR310","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0896-6273(00)80402-X","volume":"19","author":"Z Yan","year":"1997","unstructured":"Yan Z, Surmeier DJ (1997) D5 dopamine receptors enhance Zn2+-sensitive GABA(A) currents in striatal cholinergic interneurons through a PKA\/PP1 cascade. Neuron 19:1115\u20131126","journal-title":"Neuron"},{"key":"2813_CR311","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12883-015-0316-2","volume":"15","author":"S Zainal Abidin","year":"2015","unstructured":"Zainal Abidin S, Tan EL, Chan S-C et al (2015) DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson\u2019s disease patients. BMC Neurol 15:59","journal-title":"BMC Neurol"},{"key":"2813_CR312","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuropharm.2012.12.011","volume":"70","author":"Y Zengin-Toktas","year":"2013","unstructured":"Zengin-Toktas Y, Authier N, Denizot H et al (2013) Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat. Neuropharmacology 70:74\u201382","journal-title":"Neuropharmacology"},{"key":"2813_CR313","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1212\/WNL.0b013e3181d55f24","volume":"74","author":"TA Zesiewicz","year":"2010","unstructured":"Zesiewicz TA, Sullivan KL, Arnulf I et al (2010) Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the quality standards Subcommittee of the American Academy of Neurology. Neurology 74:924\u2013931","journal-title":"Neurology"},{"key":"2813_CR314","doi-asserted-by":"publisher","first-page":"RC91","DOI":"10.1523\/JNEUROSCI.20-16-j0001.2000","volume":"20","author":"X Zhuang","year":"2000","unstructured":"Zhuang X, Belluscio L, Hen R (2000) G(olf)alpha mediates dopamine D1 receptor signaling. J Neurosci 20:RC91","journal-title":"J Neurosci"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00441-018-2813-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-018-2813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-018-2813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:54:46Z","timestamp":1751446486000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00441-018-2813-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":314,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2813"],"URL":"https:\/\/doi.org\/10.1007\/s00441-018-2813-2","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"20 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.C.C. is in receipt of research grants from the French Ministry of Health, Agence Nationale pour le Recherche, Michael J Fox Foundation and honoraria for scientific advice from BMS, Zambon, Pfizer, Ipsen, Abbvie, Amarantus, Clevexel unrelated to this work. L.L.M. has received research support grants from INSERM, JNLF, The L\u2019Oreal Foundation; speech honoraria from CSL, Sanofi-Genzyme, Lundbeck Teva; and received travel funding from the Movement Disorders Society, ANAINF, Medtronic, Teva and AbbVie, outside the submitted work. H.Y., G.M., D.L.F.D.N. and F.C.B. have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}